Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EPS (Basic): 2015-2024

Historic EPS (Basic) for vTv Therapeutics (VTVT) over the last 10 years, with Dec 2024 value amounting to -$3.20.

  • vTv Therapeutics' EPS (Basic) fell 22.73% to -$1.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.27, marking a year-over-year increase of 27.81%. This contributed to the annual value of -$3.20 for FY2024, which is 67.04% up from last year.
  • As of FY2024, vTv Therapeutics' EPS (Basic) stood at -$3.20, which was up 67.04% from -$9.71 recorded in FY2023.
  • In the past 5 years, vTv Therapeutics' EPS (Basic) ranged from a high of -$0.18 in FY2020 and a low of -$9.98 during FY2022.
  • For the 3-year period, vTv Therapeutics' EPS (Basic) averaged around -$7.63, with its median value being -$9.71 (2023).
  • As far as peak fluctuations go, vTv Therapeutics' EPS (Basic) spiked by 69.49% in 2020, and later tumbled by 4,505.56% in 2021.
  • Yearly analysis of 5 years shows vTv Therapeutics' EPS (Basic) stood at -$0.18 in 2020, then slumped by 4,505.56% to -$8.29 in 2021, then declined by 20.39% to -$9.98 in 2022, then climbed by 2.71% to -$9.71 in 2023, then spiked by 67.04% to -$3.20 in 2024.